Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2024, Vol. 38 ›› Issue (1): 13-20.doi: 10.6040/j.issn.1673-3770.0.2022.479

• Original Article • Previous Articles     Next Articles

Efficacy and safety of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis:a Meta-analysis

ZHANG Zhen, YANG Zhuoying, ZHOU Jiani, ZHANG Dawei, CHEN Renjie   

  1. Department of Otolaryngology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China
  • Published:2024-01-12

PDF (PC)

128

Abstract: Objective This study aimed to evaluate the clinical efficacy and safety of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis and provide evidence-based guidelines for rational drug use. Methods Cochrane Library, Web of Science, PubMed, ClinicalTrials, China National Knowledge Infrastructure, WanFang, Chinese Scientific Journal, and Chinese Biomedical Databases were searched. Randomized controlled trials were collected to compare ciclesonide(trial groups)with placebo(control groups)for the treatment of allergic rhinitis. All RCTs were randomized from the establishment of the databases to October 2022. According to the inclusion and exclusion criteria, the literature was strictly screened by two evaluators. Additionally, the quality of the included studies was assessed. The Review Manager(version 5.4)software was used for statistical analyses. Results A total of 9 studies were included in this meta-analysis. In terms of efficacy, ciclesonide reduced instantaneous total nasal symptom score(weighted mean difference ［WMD］=-0.43; 95%convidence interval ［CI; -0.63,-0.23］; P<0.01)and instantaneous single nasal score ［WMD=-0.19; 95%CI(-0.23,-0.05); P<0.01］. Ciclesonide also reduced the role of reflective total nasal symptom score ［WMD=-0.66; 95%CI(-0.80,-0.52)］; P<0.01)and reflective nasal single score ［WMD=-0.23; 95%CI(-0.26,-0.21); P<0.01］. It also reduced instantaneous ocular symptom score ［WMD=-0.19; 95%CI ［-0.22,-0.15］; P<0.01］; instantaneous ocular symptom total score ［WMD=-0.28; 95%CI(-0.56,-0.00); P=0.05］; and reflective ocular symptom total score ［WMD=-0.27; 95%CI(-0.54,-0.00); P=0.05］. Moreover, ciclesonide reduced mirrored ocular single score ［WMD=-0.17; 95%CI(-0.21,-0.14); P<0.01］ and related scores of the rhinoconjunctivitis quality of life scale ［WMD=-0.61; 95%CI(-0.76,-0.47); P<0.01］. Regarding safety, the incidence of adverse events was not increased in the experimental group compared with the control group ［odds ratio=0.96; 95%CI(0.76,1.20); P=0.72］. Conclusion Ciclesonide nasal spray was effective in the treatment of seasonal allergic rhinitis. Furthermore, it did not increase the incidence of adverse events. Ciclesonide has been shown to have good safety and tolerance and the value of further clinical promotion.

Key words: Ciclesonide, Seasonal allergic rhinitis, Meta-analysis

CLC Number: 

  • R765.21
[1] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 106-129. doi:10.3760/cma.j.cn115330-20211228-00828
[2] Zieglmayer P, Schmutz R, Lemell P, et al. Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis[J]. Clinical & Experimental Allergy, 2020, 50(9): 1065-1077. doi:10.1111/cea.13691
[3] 李丽莎, 关凯, 李俊达, 等. 季节性变应性鼻炎预防治疗对患者生活质量的影响及相关转录组学研究[J]. 中华预防医学杂志, 2021, 55(5): 606-612. doi:10.3760/cma.j.cn112150-20210228-00198 LI Lisha, GUAN Kai, LI Junda, et al. The effect on patient life quality of prophylactic treatment to seasonal allergic rhinitis and related transcriptomics research[J]. Chinese Journal of Preventive Medicine, 2021, 55(5): 606-612. doi:10.3760/cma.j.cn112150-20210228-00198
[4] Sampieri G, Namavarian A, Lee JJW, et al. Hypothalamic-pituitary-adrenal axis suppression and intranasal corticosteroid use: a systematic review and meta-analysis[J]. International Forum of Allergy & Rhinology, 2022, 12(1): 11-27. doi:10.1002/alr.22863
[5] Damia Ski P, Kardas G, Panek M, et al. Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions[J]. Expert Opinion on Drug Safety, 2022, 21(4): 499-515. doi:10.1080/14740338.2022.1999926
[6] Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial(COVERAGE)[J]. Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, 28(7): 1010-1016. doi:10.1016/j.cmi.2022.02.031
[7] Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19[J]. The Cochrane Database of Systematic Reviews, 2022, 3(3): CD015125. doi:10.1002/14651858.CD015125
[8] Tsuji G, Nakajima S, Watashi K, et al. Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication[J]. Journal of Pharmacological Sciences, 2022, 149(3): 81-84. doi:10.1016/j.jphs.2022.04.001
[9] Ellaithy HM, Youssef A, Elhusseney SS, et al. Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks[J]. Drug Delivery, 2021, 28(1): 826-843. doi:10.1080/10717544.2021.1905747
[10] Trevisiol S, Moulard Y, Kaadia Z, et al. LC-HRMS/MS study of the prodrug ciclesonide and its active metabolite desisobutyryl-ciclesonide in plasma after an inhalative administration to horses for doping control purposes[J]. Drug Testing and Analysis, 2022, 14(2): 252-261. doi:10.1002/dta.3174
[11] Qi Yang. The efficacy and safety of ciclesonide for the treatment of perennial allergic rhinitis: a systematic review and meta-analysis[J]. Brazilian Journal of Otorhinolaryngology, 2019, 85(3): 371-378. doi:10.1016/j.bjorl.2018.10.008
[12] Andrade C. Understanding the basics of meta-analysis and how to read a forest plot: As simple as it gets[J]. The Journal of Clinical Psychiatry, 2020, 81(5): 20f13698. doi:10.4088/JCP.20f13698
[13] Ratner P, Jacobs R, Mohar D, et al. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology, 2010, 105(6): 471-479. doi:10.1016/j.anai.2010.09.024
[14] Craig MD. Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology, 2009, 103(2): 166-173. doi:10.1016/S1081-1206(10)60171-8
[15] Peter MD. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology, 2009, 102(1): 62-68. doi:10.1016/S1081-1206(10)60110-X
[16] Patel P, Patel D, Kunjibettu S, et al. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis[J]. Ear, Nose, & Throat Journal, 2008, 87(6): 340-353
[17] Ratner PH, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen[J]. Allergy and Asthma Proceedings, 2012, 33(1): 27-35. doi:10.2500/aap.2012.33.3490
[18] Ratner PH, Wingertzahn MA, VAN BAVEL JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology, 2006, 97(5): 657-663. doi:10.1016/S1081-1206(10)61097-6
[19] Effect of citrate on the coagulation system in patients receiving CRRT(citroco)[EB/OL].[2019-10-22]. https://clinicaltrials.gov/study/NCT02486614
[20] Efficacy and safety of ciclesonide nasal spray in participants with seasonal allergic rhinitis(SAR)in Russia)[EB/OL].[2019-10-22]. https://clinicaltrials.gov/ct2/show/ NCT01458275
[21] Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA care pathways for allergen immunotherapy[J]. Allergy, 2019, 74(11): 2087-2102. doi:10.1111/all.13805
[22] Fu TT, Zhao Y, Yang FF, et al. Ciclesonide and budesonide suspensions for nebulization delivery: an in vivo inhalation biopharmaceutics investigation[J]. International Journal of Pharmaceutics, 2018, 549(1/2): 21-30. doi:10.1016/j.ijpharm.2018.07.048
[23] Jacobs RL. Ciclesonide for the treatment of seasonal allergic rhinitis[J]. Expert Review of Clinical Immunology, 2011, 7(6): 735-741. doi:10.1586/eci.11.70
[24] Humbert M. Ciclesonide: a novel inhaled corticosteroid[J]. Expert Opinion on Investigational Drugs, 2004, 13(10): 1349-1360. doi:10.1517/13543784.13.10.1349
[25] Mukker JK, Singh RSP, Derendorf H. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids[J]. Journal of Pharmaceutical Sciences, 2016, 105(9): 2509-2514. doi:10.1016/j.xphs.2016.05.004
[26] 龚霄阳, 程雷. 新冠疫情期间基于门诊患者的变应性鼻炎患者比例构成分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 245-253. doi:10.6040/j.issn.1673-3770.0.2021.422 GONG Xiaoyang, CHENG Lei. Analysis of proportion of outpatients with allergic rhinitis during the coronavirus infectious disease 2019 pandemic[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 245-253. doi:10.6040/j.issn.1673-3770.0.2021.422
[27] Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells[J]. bioRxiv, 2020. doi: 10.1101/2020.08.22.258459. doi:10.1101/2020.08.22.258459
[28] Song JY, Yoog JG, Seo YB, et al. Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomized, open-label, phase 2 trial[J]. Journal of Clinical Medicine, 2021, 10(16): 3545. doi:10.3390/jcm10163545
[29] Hsu DW, Suh JD. Anatomy and physiology of nasal obstruction[J]. Otolaryngologic Clinics of North America, 2018, 51(5): 853-865. doi:10.1016/j.otc.2018.05.001
[30] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary[J]. Otolaryngolo Head Neck Surg, 2015, 152(2): 197-206. doi:10.1177/0194599814562166
[31] 杨钦泰, 陈建军, 谭国林, 等. 鼻用糖皮质激素治疗变应性鼻炎专家共识(2021, 上海)[J]. 中国耳鼻咽喉颅底外科杂志, 2021, 27(4): 365-371. doi:10.11798/j.issn.1007-1520.202140001 YANG Qintai, CHEN Jianjun, TAN Guolin, et al. Expert consensus on the management of allergic rhinitis with intranasal corticosteroid(2021, Shanghai)[J]. Chinese Journal of Otorhinolaryngology-Skull Base Surgery, 2021, 27(4): 365-371. doi:10.11798/j.issn.1007-1520.202140001
[32] Urdaneta E, Gates D. Effect of mometasone furoate nasal spray on moderate-to-severe nasal congestion in seasonal allergic rhinitis: a responder analysis[J]. Allergy and Asthma Proceedings, 2019, 40(3): 173-179. doi:10.2500/aap.2019.40.4214
[33] 刘英, 叶小静, 赵春丽, 等. 季节性变应性鼻炎预防性治疗观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 37-40. doi:10.6040/j.issn.1673-3770.0.2017.108 LIU Ying, YE Xiaojing, ZHAO Chunli, et al. Preventive treatment for seasonal allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(3): 37-40. doi:10.6040/j.issn.1673-3770.0.2017.108
[1] BI Xiaoyun, MA Benxu, WANG Xinru, LI Xuhao, YANG Jiguo. Meta-analysis of randomized controlled trials of acupoint application in treatment of children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 75-85.
[2] HOU Lingxiao, ZHANG Changcui, XU Anting, FAN Xintai, WANG Na. Role of CD4+ T cells from nasal mucosa in the pathogenesis of patients with seasonal allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 96-104.
[3] LI Zepeng, LI Wenjian, SUN Zhijia. Net Meta-analysis and data mining of patients with acute pharyngitis managed with Chinese medicine [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 111-118.
[4] ZHAI Rui, LI Yuan, YU Jinglong, CHEN Xi, ZHENG Youyou, LIU Zhaolan, WANG Junhong. Meta-analysis of clinical intradermal acupuncture efficacy for treatment of allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 35-45.
[5] YIN Kexin, SUN Wu, LIU Hongyan, XIA Yanting, WEI Qiping, ZHOU Jian. Agreement of intraocular pressure measured by Icare Home tonometer and Goldmann applanation tonometer: a Meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(2): 75-83.
[6] LIN Manqing, ZHOU Min, CHEN Tengyu, LI-Dan, FANG Caishan, WANG Ruizhi, ZHU Jinxiang, RUAN-Yan, XU Huixian, WANG Peiyuan. Meta-analysis of the efficacy and safety of traditional Chinese medicine for nasal irrigation in the treatment of chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 209-225.
[7] JIANG Xuelian, ZHANG Jingyue, WEI Xudong. Evaluation of the efficacy and potential mechanism of biyuan tongqiao granules in chronic sinusitis treatment based on Meta-analysis bridging network pharmacology [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 226-236.
[8] HUANG Kaiyue, LI Xueqing, HAN Gouxin, ZHANG Qinxiu. Meta-analysis of acupoint catgut embedding in the treatment of allergic rhinitis based on the theory of “lung and spleen” [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 266-274.
[9] LIU Shanshan, HAN Shujing, WANG Xiaoxu, LI Yanhong, NI Xin, ZHANG Jie. Hearing loss in children after bacterial meningitis: a systematic review and meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 48-54.
[10] LIU Yi, YU Mingkun, SUN Wei, SHAO Zhen, HU Yuanyuan, BI Hongsheng. The effectiveness and safety of orthokeratology on controlling myopia of children: a meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(6): 92-100.
[11] ZHONG Liping, GUAN Xilong, WANG Jingjing, TANG Yong. Intratympanic injections and systemic glucocorticoid treatment for sudden hearing loss: a systematic review and Meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 1-10.
[12] LIN Xiaoyan, LI Jing, MA Zhiqi, LI Yilin, GAO Xinyi, LI Yong. Therapeutic and anti-allergic effects of probiotics on allergic rhinitis: a meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 70-80.
[13] TAN Fengwu, DENG Yaping, LI Kehua. The therapeutic effects of low temperature plasma radiofrequency ablation and CO2 laser surgery on early glottic carcinoma: a Meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(6): 63-71.
[14] ObjectiveTo compare the effects of intra-arterial thrombolysis and traditional treatment in central retinal artery occlusion(CRAO). MethodsWe searched the Pubmed, Embase, Clinical.gov, CNKI, and Wan Fang databases for related studies that were published up to May , . We included clinical controls that compared intra-arterial thrombolysis and conventional treatment in CRAO. The random effect model and R software were used for data analysis. ResultsWe identified seven studies including CRAO patients. Meta-analysis results of two randomized controlled trials(RCTs)showed that there was no significant difference in visual acuity improvement between CRAO patients treated with arterial thrombolysis therapy and those with conventional therapy(RR: ., % confidence interval .-., P=.). Meta-analysis results of five cohort studies indicated that compared with conventional therapy, arterial thrombolysis therapy significantly improved visual acuity(RR: ., % confidence interval .-., P<.). The difference between thrombolysis therapy and conventional therapy may be caused by the different treatment time windows in patients. Concerning the adverse reactions after treatment, two RCTs and five cohort studies showed that the adverse reactions in the thrombolysis group are significantly higher than those in the conventional treatment group. ConclusionAlthough intra-arterial thrombolysis therapy has therapeutic potential in CRAO patients, there is still insufficient clinical evidence to prove its effectiveness and safety. Further studies with a large sample and high quality RCTs are required.. Intra-arterial thrombolysis for central retinal artery occlusion: a Meta-analysisCHEN Xi, LI Shanshan, ZHAO Lu, YOU Ran, WANG Yanling Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 28-34.
[15] JI Di, CHEN Xiang, YU Lin. Soft palate surgeries with hyoid bone suspension for obstructive sleep apnea hypopnea syndrome with glossoptosis: a meta-analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 124-130.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd